In such tumors, the final diagnosis depends on the application of immunohistochemical markers that point to the diagnosis of prostate origin, in particular PSMA (see below, i.e., PSMA and aggressive variant prostate cancer), and the exclusion of malignancies from other sites, including the bladder, such as the presence of GATA3 (Figure 1B, insert) and uroplakins. The gene discussed is FOLH1; the disease is Familial prostate cancer.